Zymeworks (ZYME) Jefferies Global Healthcare Conference 2026 summary

Leadership and company overview

• Newly appointed Chief Business Officer highlighted the company's strong R&D innovation and robust financial position, emphasizing a dual business model: internal R&D and external partnerships.

• The company manages a portfolio of wholly owned and partnered assets, focusing on oncology and immunology.

Zanidatamab (Zani) updates and outlook

• Zanidatamab demonstrated statistically significant survival benefit in frontline gastric cancer, with broad efficacy across PD-L1 subgroups.

• Priority review for sBLA with PDUFA date set for August 25, with expectations for robust global adoption.

• Expansion opportunities include the EmpowHER-303 breast cancer trial, with top-line readout expected late 2027 or early 2028.

• Early data suggest potential benefit in post-Enhertu settings due to Zani’s unique mechanism.

ZW191 (Folate receptor alpha ADC) progress

• ZW191 shows strong activity and tolerability in early data, with dose optimization cohorts fully enrolled and about 60 patients in expansion.

• Data from expansion expected at ESMO GYN, focusing on folate expression subgroups and dose response.

• Preclinical data support potential for combination therapies due to favorable tolerability profile.